Company Profile

Viamune Inc
Profile last edited on: 4/10/23      CAGE: 6FN73      UEI: ZN8PG6JAKMN5

Business Identifier: Immunotherapy for patients with advanced cancers.
Year Founded
2011
First Award
2017
Latest Award
2021
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

220 Riverbend Road
Athens, GA 30602
   (706) 372-4261
   N/A
   N/A
Location: Single
Congr. District: 10
County: Clarke

Public Profile

Viamune is structured around investigating related tumor-associated glycoproteins to expand the firm's drug therapy pipeline. Offering a fully synthetic vaccine platform that generates robust immune responses to tumor-specific targets, tViamune's patented technology provides a unique path to targeting structures found only on tumor cells. The company is developing an immunotherapy vaccine targeting tumor-specific MUC1, a cell-surface glycoprotein designed to help cancerous cells form a barrier against chemotherapeutic drugs. ViaMune’s lead compound — MTI, still in the pre-clinical stage — promises to target aberrant MUC1 specifically and to defeat tolerance to tumor antigens - therebyaiding in tumor treatmen

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Key People / Management

  Geert-Jan Boons -- President and Chief Scientific Officer

  Anthony Prudden

Company News

There are no news available.